Paper. Novick AM, Love TM, Johnson RL et al.. Journal of Affective Disorders, 30 Oct 2026.
Tags: RCT, Psilocybin, Depression.
Psilocybin missed its primary anhedonia endpoint at week 1 but separated by week 8.
In a 20-person double-blind trial in treatment-resistant depression, the week-1 DARS difference was 11.2 (95% CI −1.0 to 23.3, p=0.073); the week-8 secondary was 14.7 (CI 2.5 to 26.8). Separately, a meta-analysis of 5 LSD RCTs (N=227) found a standardized mean difference of −0.69 on depression symptoms, and the first open-label MDMA-assisted therapy trial in veterans with comorbid PTSD and alcohol use disorder (N=10) reported 90% retention.
How much weight it carries: Main trial is a 20-person pilot whose primary endpoint was negative; the supporting meta-analysis pools 227 patients across heterogeneous LSD trials with likely unblinding. (Humans, RCT, Double-blind, Placebo-controlled, Small sample, Null result, Meta-analysis, Open-label, n = 20)